115 related articles for article (PubMed ID: 26373273)
21. Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma.
Dong X; Deng Q; Nie X; Zhang M; Jia W; Chen C; Xu C; Xu R
Exp Mol Pathol; 2015 Apr; 98(2):192-9. PubMed ID: 25617528
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
23. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
24. "Smad"eningly erratic: target gene methylation determines whether TGFbeta promotes or suppresses malignant glioma.
Kesari S; Jackson-Grusby L; Stiles CD
Dev Cell; 2007 Mar; 12(3):324-5. PubMed ID: 17336898
[TBL] [Abstract][Full Text] [Related]
25. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas.
Chen HY; Shao CJ; Chen FR; Kwan AL; Chen ZP
Int J Cancer; 2010 Apr; 126(8):1944-1954. PubMed ID: 19626585
[TBL] [Abstract][Full Text] [Related]
26. DNA hypomethylation of CD133 promoter is associated with recurrent glioma.
Sun B; Wan Z; Shen J; Ni L; Chen J; Cui M; Ni H; Shi W; Shi J
Oncol Rep; 2016 Aug; 36(2):1062-8. PubMed ID: 27374817
[TBL] [Abstract][Full Text] [Related]
27. Gene regulation by methylation.
Mueller WC; von Deimling A
Recent Results Cancer Res; 2009; 171():217-39. PubMed ID: 19322547
[TBL] [Abstract][Full Text] [Related]
28. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
Xie H; Tubbs R; Yang B
Int J Clin Exp Pathol; 2015; 8(1):636-42. PubMed ID: 25755756
[TBL] [Abstract][Full Text] [Related]
29. Under explored epigenetic modulators: role in glioma chemotherapy.
Chen YH; Zeng WJ; Wen ZP; Cheng Q; Chen XP
Eur J Pharmacol; 2018 Aug; 833():201-209. PubMed ID: 29864410
[TBL] [Abstract][Full Text] [Related]
30. [The epigenetic mechanisms at work in pediatric gliomas].
Larsen CJ
Bull Cancer; 2014 Apr; 101(4):341. PubMed ID: 24918236
[No Abstract] [Full Text] [Related]
31. B-cell CLL/lymphoma 3 promotes glioma cell proliferation and inhibits apoptosis through the oncogenic STAT3 pathway.
Wu J; Li L; Jiang G; Zhan H; Wang N
Int J Oncol; 2016 Dec; 49(6):2471-2479. PubMed ID: 27748795
[TBL] [Abstract][Full Text] [Related]
32. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
33. CBX7 is a glioma prognostic marker and induces G1/S arrest via the silencing of CCNE1.
Yu T; Wu Y; Hu Q; Zhang J; Nie E; Wu W; Wang X; Wang Y; Liu N
Oncotarget; 2017 Apr; 8(16):26637-26647. PubMed ID: 28460453
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
Fan TY; Wang H; Xiang P; Liu YW; Li HZ; Lei BX; Yu M; Qi ST
Int J Clin Exp Pathol; 2014; 7(10):6662-70. PubMed ID: 25400745
[TBL] [Abstract][Full Text] [Related]
35. Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas.
Wang ZL; Zhang CB; Cai JQ; Li QB; Wang Z; Jiang T
J Exp Clin Cancer Res; 2015 Oct; 34():127. PubMed ID: 26502731
[TBL] [Abstract][Full Text] [Related]
36. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
37. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
38. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
[TBL] [Abstract][Full Text] [Related]
39. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
40. HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme.
Herranz M; Padín-Iruegas ME; Martínez-Lago N; Losada SA; Raña-Díez P; Vázquez EB; Carrera JJ; Antúnez JR; Ruibal A; López-López R
Mol Neurobiol; 2016 Apr; 53(3):1802-1807. PubMed ID: 25752997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
